Morgan Stanley resumed coverage on Natera with a new price target
$NTRA
Medical Specialities
Health Care
Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/26/2026 | $310.00 | Outperform | Bernstein |
| 6/12/2026 | $275.00 | Outperform | RBC Capital Mkts |
| 6/2/2026 | $260.00 | Outperform | Wolfe Research |
| 4/14/2026 | Outperform | William Blair | |
| 1/7/2026 | $300.00 | Buy | Citigroup |
| 12/2/2025 | $265.00 | Overweight | Morgan Stanley |
| 10/27/2025 | $172.00 | Underperform → Neutral | BNP Paribas Exane |
| 9/22/2025 | $175.00 | Equal Weight | Wells Fargo |
Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settingsNatera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:Kidney: 6 tests in year 1; 4 per year in years 2-3. "For-cause" coverage remains unchanged.Heart: 12 tests in year 1; 4 p
Signatera is the first personalized molecular residual disease (MRD) test for solid tumors to receive IVDR certification in the EU Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the world’s most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platform — including the assay, specimen collection kit, and associated software — underwent a comprehe
Newly published study shows Signatera MRD-positive patients lived longer with adjuvant chemotherapy, while MRD-negative patients saw no significant benefit First predictive data for overall survival from GALAXY trial in patients with oligo-metastatic CRC in the liver Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases (CRLM). The data was also presented as an oral presentation at the 2026 European Society for Medical Oncology Gastrointestinal (ESMO
Bernstein resumed coverage of Natera with a rating of Outperform and set a new price target of $310.00
RBC Capital Mkts resumed coverage of Natera with a rating of Outperform and set a new price target of $275.00
Wolfe Research resumed coverage of Natera with a rating of Outperform and set a new price target of $260.00
8-K - Natera, Inc. (0001604821) (Filer)
144 - Natera, Inc. (0001604821) (Subject)
8-K/A - Natera, Inc. (0001604821) (Filer)
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced the appointments of Thomas Lynch, M.D., and Eric Rubin, M.D., to the Company's board of directors. "Tom and Eric have helped lead some of the most important advances in modern oncology, and we are thrilled to welcome them to the Board," said Matthew Rabinowitz, Ph.D., co-founder of Natera and executive chairman of the board. "Their deep expertise across evidence generation, clinical development, biopharma, and leading cancer research institutions will be incredibly valuable as Natera continues expanding the impact of precision diagnostics in patient care." "The oncology field is moving t
Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on
Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter of 2025. Processed approximately 1,013,600 tests in the first quarter of 2026, compared to approximately 855,100 tests in the first quarter of 2025, an increase of 18.5%. Women's Health generated the second highest quarter
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its first quarter ended March 31, 2026, after the market closes on May 7, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2026 Financial Results Date: May 7, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/443070230 A w
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today highlighted Allogene Therapeutics' (NASDAQ:ALLO) interim futility analysis from its registrational ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel), an investigational allogeneic anti-CD19 CAR T therapy, in first-line (1L) consolidation large B-cell lymphoma (LBCL). The ALPHA3 trial is enrolling patients with LBCL who test positive for molecular residual disease (MRD) following 1L therapy. These patients are then randomized either to cema-cel, an investigational allogeneic anti-CD19 CAR T therapy developed by Allogene, or observation. The interim analysis showed that 58.3% of MRD-positive pat
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)